Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 7/20 | 0.68 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.55 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.55 |
| ▸ | GRM5 | P41594 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3601882 | 0.83 | KIF11 (0.46) | KIF11GRM5RAB9ATRPV1 | |
| SCHEMBL3597393 | 0.82 | KIF11 (0.44) | KIF11GRM5RAB9ATRPV1GAA | |
| SCHEMBL16208518 | 0.81 | KIF11 (1.00) | KIF11GAA | |
| SCHEMBL9312317 | 0.80 | GRM5 (0.53) | KIF11NTRK1NTRK3GRM5KMT2A | |
| SCHEMBL16208483 | 0.80 | KIF11 (0.81) | KIF11TRPV1 | |
| SCHEMBL25566649 | 0.80 | CA12 (0.54) | KIF11NTRK1TRPV1KDR | |
| SCHEMBL396156 | 0.78 | DDX3X (0.59) | TRPV1ALDH1A1 | |
| SCHEMBL3607060 | 0.78 | KIF11 (0.41) | KIF11GRM5RAB9ATRPV1GAA | |
| SCHEMBL4548162 | 0.77 | KMT2A (0.87) | NTRK1KMT2AMAPTMEN1HTT | |
| SCHEMBL25566268 | 0.76 | KDR (0.65) | TRPV1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168182-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2010-07-01 | — | — | US | disclosed |
| US-20100168182-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2010-07-01 | — | — | US | disclosed |
| US-20100168182-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2010-07-01 | — | — | US | disclosed |
| EP-2102190-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008073480-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073480-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168182-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | NTRK2, PDGFRB, PDGFRA | KIF11 1787/4885NTRK1 4/4885NTRK3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.